The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era
Tuberculosis is the number one cause of death from infectious disease globally and drug-
resistant forms of the disease are a major risk to global health security. On the occasion of …
resistant forms of the disease are a major risk to global health security. On the occasion of …
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
MJA Reid, N Arinaminpathy, A Bloom, BR Bloom… - The Lancet, 2019 - thelancet.com
Executive summary Tuberculosis can be treated, prevented, and cured. Rapid, sustained
declines in tuberculosis deaths in many countries during the past 50 years provide …
declines in tuberculosis deaths in many countries during the past 50 years provide …
Tuberculosis in children
CM Perez-Velez, BJ Marais - New England Journal of Medicine, 2012 - Mass Medical Soc
Tuberculosis in Children | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
[HTML][HTML] Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative …
Background The recent series of reviews conducted within the Global Action Plan for
Pneumonia and Diarrhoea (GAPPD) addressed epidemiology of the two deadly diseases at …
Pneumonia and Diarrhoea (GAPPD) addressed epidemiology of the two deadly diseases at …
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts
Recent data for the global burden of disease reflect major demographic and lifestyle
changes, leading to a rise in non-communicable diseases. Most countries with high levels of …
changes, leading to a rise in non-communicable diseases. Most countries with high levels of …
Scaling up interventions to achieve global tuberculosis control: progress and new developments
M Raviglione, B Marais, K Floyd, K Lönnroth… - The Lancet, 2012 - thelancet.com
Tuberculosis is still one of the most important causes of death worldwide. The 2010 Lancet
tuberculosis series provided a comprehensive overview of global control efforts and …
tuberculosis series provided a comprehensive overview of global control efforts and …
Drug-resistant tuberculosis: time for visionary political leadership
I Abubakar, M Zignol, D Falzon… - The Lancet infectious …, 2013 - thelancet.com
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the
highly cost-effective directly observed treatment short-course programme to control the …
highly cost-effective directly observed treatment short-course programme to control the …
Human gene expression profiles of susceptibility and resistance in tuberculosis
J Maertzdorf, D Repsilber, SK Parida, K Stanley… - Genes & …, 2011 - nature.com
Tuberculosis (TB) still poses a profound burden on global health, owing to significant
morbidity and mortality worldwide. Although a fully functional immune system is essential for …
morbidity and mortality worldwide. Although a fully functional immune system is essential for …
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities
R McNerney, M Maeurer, I Abubakar… - Journal of Infectious …, 2012 - academic.oup.com
Tuberculosis is unique among the major infectious diseases in that it lacks accurate rapid
point-of-care diagnostic tests. Failure to control the spread of tuberculosis is largely due to …
point-of-care diagnostic tests. Failure to control the spread of tuberculosis is largely due to …
WHO's 2013 global report on tuberculosis: successes, threats, and opportunities
A Zumla, A George, V Sharma, N Herbert - The lancet, 2013 - thelancet.com
8 Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and
stroke events with atorvastatin in hypertensive patients who have average or lower-than …
stroke events with atorvastatin in hypertensive patients who have average or lower-than …